Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Novaccess Global Inc XSNX

Healthcare Biotechnology
NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is... see more

Recent & Breaking News (OTCQB:XSNX)

NovAccess Global Files Patent with Cedars-Sinai to Advance its Brain Cancer Fighting Vaccine Platform

Accesswire 11 days ago

NovAccess Global Advisory on Annual Meeting of Shareholders

Accesswire May 7, 2024

NovAccess Global Announces New License to Advance its Immunotherapy Platform

Accesswire April 30, 2024

NovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of Shareholders

Accesswire March 1, 2024

NovAccess Global Announces $10.7 Million Financing

Accesswire January 2, 2024

NovAccess Global Inc. to Present at the December 7th Virtual Investor Summit

Newsfile December 1, 2023

NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board

Accesswire November 10, 2023

NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy Platform

Accesswire July 27, 2023

NovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness Day

Accesswire July 13, 2023

NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine Division

Accesswire June 16, 2023

NovAccess Global Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalized Healthcare Therapies

Accesswire June 1, 2023

NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine Advancements

Accesswire May 11, 2023

Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award

Accesswire March 15, 2023

NovAccess Global to Present at World Orphan Drug Congress

Accesswire February 16, 2023

NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress

Accesswire February 3, 2023

NovAccess Global Announces Fireside Chat with Dr. Christopher Wheeler, the Company's Lead Scientist and President of its StemVax Therapeutics Division

Accesswire January 5, 2023

NovAccess Global Announces Initial Fireside Chat with Glioblastoma Patient Advocate

Accesswire November 22, 2022

NovAccess Global Appoints Healthcare IP Consultant Dr. Peter Weinstein to Scientific Advisory Board

Accesswire November 10, 2022

NovAccess Global Announces Virtual Annual Shareholders' Meeting

Accesswire November 8, 2022

NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1

Accesswire October 26, 2022